Blood

Vol. 146, Issue 25 Issue 25 2025
18
Articles

Articles in this Issue

Rbm38 binds <i>Fech</i> pre-mRNA to prevent anemia and porphyria

Xiuli An Dec 18, 2025 pp. 3016-3017 10.1182/blood.2025031227

Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia

Tina Bagratuni, Ourania Theologi, Christos Vlachos et al. Dec 18, 2025 pp. 3086-3097 10.1182/blood.2025030177

Abstract Immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (IgM-MGUS) and asymptomatic Waldenström macroglobulinemia (WM; aWM) are precursor conditions of s...

Exhaustion is getting complicated

William J. Murphy Dec 18, 2025 pp. 3008-3010 10.1182/blood.2025031002

Outnumbered: T-cell dominance breaks BCMA-TCE resistance

Paola Neri Dec 18, 2025 pp. 3010-3011 10.1182/blood.2025031063

Molecular modeling of Waldenström macroglobulinemia

Gareth J. Morgan, Faith E. Davies Dec 18, 2025 pp. 3012-3013 10.1182/blood.2025031066

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Françoise Kraeber-Bodéré, Bastien Jamet, Sonja Zweegman et al. Dec 18, 2025 pp. 3050-3058 10.1182/blood.2025030084

Abstract The CASSIOPEIA trial demonstrated superior progression-free survival (PFS) with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (D-VTd) induction...

An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden

Erin W. Meermeier, Kirsten Pfeffer, Caleb K. Stein et al. Dec 18, 2025 pp. 3072-3085 10.1182/blood.2025029215

Abstract Bispecific T-cell engagers (TCEs) targeting B-cell maturation antigen (BCMA) and CD3, induce deep hematologic responses in ∼60% of heavily pretreated patients with multipl...

<i>LEF1</i> intragenic deletions: is Wnt’er coming for T-ALL?

A. Rita Fragoso, João T. Barata Dec 18, 2025 pp. 3005-3006 10.1182/blood.2025030884

MECOM is a master repressor of myeloid differentiation through dose control of <i>CEBPA</i> in acute myeloid leukemia

Dorien Pastoors, Marije Havermans, Roger Mulet-Lazaro et al. Dec 18, 2025 pp. 3098-3105 10.1182/blood.2025028914

Abstract The transcription factor MECOM, located at 3q26, is essential for hematopoietic stem cells in healthy individuals. Enhancer translocations, due to 3q26 rearrangements, dri...

Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients

Stephanie T. Isaac, David C. Bishop, Fahad Shaikh et al. Dec 18, 2025 pp. 3124-3128 10.1182/blood.2025029057

Abstract Human herpesvirus 6 reactivation in chimeric antigen receptor T-cell recipients is reported to be rare. Our patient cohort (n = 119) experienced a sevenfold higher inciden...

Breaking the silence: restoring <i>CEBPA</i> to fight leukemia

Nicola K. Wilson, Berthold Göttgens Dec 18, 2025 pp. 3014-3015 10.1182/blood.2025031363

More than an emotional support PET

Jens Hillengass Dec 18, 2025 pp. 3006-3008 10.1182/blood.2025031179

Rbm38 deficiency impairs erythroid heme biosynthesis and induces porphyria via reduced ferrochelatase expression

Xinshu Xie, Ailing Zou, Lei Zhang et al. Dec 18, 2025 pp. 3106-3123 10.1182/blood.2025028783

Abstract RNA splicing and processing are critical for erythropoiesis, because dysregulation of RNA splicing ultimately disrupts protein synthesis. The RNA-binding protein Rbm38 is...

<i>LEF1</i> intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL

Manon Delafoy, Mickaël F. Bonnet, Etienne Lengliné et al. Dec 18, 2025 pp. 3036-3049 10.1182/blood.2025030161

Abstract T-cell acute lymphoblastic leukemia (T-ALL) represents a group of aggressive hematological malignancies characterized by unfavorable prognosis, urging the need for innovat...

Chronic NK cell activation results in a dysfunctional, tissue resident–like state mediated by KLF2 deficiency

Jacob A. Myers, Rih-Sheng Huang, Shee Kwan Phung et al. Dec 18, 2025 pp. 3059-3071 10.1182/blood.2024027763

Abstract Adoptive transfer of natural killer (NK) cells can induce complete remissions in 30% to 50% of patients with refractory acute myeloid leukemia and lymphoma. Although blood...

CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias

Travis J. Fleming, Mateusz Antoszewski, Sander Lambo et al. Dec 18, 2025 pp. 3019-3035 10.1182/blood.2025028954

Abstract Acute myeloid leukemias (AMLs) have an overall poor prognosis with many high-risk cases co-opting stem cell gene regulatory programs, but the mechanisms through which thes...

Premaintenance PET in patients with myeloma

Dec 18, 2025 pp. 3130-3130 10.1182/blood.2025032271

Leukemic phase of hepatosplenic T-cell lymphoma

J. Stephen Stalls, David C. Park Dec 18, 2025 pp. 3129-3129 10.1182/blood.2025031068

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page